674 related articles for article (PubMed ID: 17021057)
1. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
Isham N; Ghannoum MA
J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
[TBL] [Abstract][Full Text] [Related]
3. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Heyn K; Tredup A; Salvenmoser S; Müller FM
Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
[TBL] [Abstract][Full Text] [Related]
4. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
Miyazaki M; Horii T; Hata K; Watanabe NA; Nakamoto K; Tanaka K; Shirotori S; Murai N; Inoue S; Matsukura M; Abe S; Yoshimatsu K; Asada M
Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
9. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
10.
Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
[TBL] [Abstract][Full Text] [Related]
11. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
14. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
Espinel-Ingroff A
J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
[TBL] [Abstract][Full Text] [Related]
15. Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.
Peter J; Armstrong D; Lyman CA; Walsh TJ
J Clin Microbiol; 2005 Aug; 43(8):3788-92. PubMed ID: 16081911
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
18. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
19. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
20. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
